Home

Anixa Biosciences Announces $5 Million Share Repurchase Program

TW's Take: this is a display of confidence in the upcoming results from both programs. I expect to see positive CAR-T data in particular...

Close the Gap!

What a week in the TW universe. It started out slow with more of the consistent, across the board selling that has come to...

A Tale of Two Tech Companies

With the first half of 2024 now in the record books, it was certainly one that microcap investors would love to forget. The large...

Atomera Enables Breakthrough RF Substrates for 5G Advanced and 6G Products

TW's Take: seems like exciting news but need to get more understanding of the levels of performance increase which would need to be significantly...

Not Totally Blind…INmune Provides A Clue

This week I'm starting the newsletter with a discussion on INmune Bio (INMB). There are two reasons for this. Firstly, the company put out...

Premium Subscriber Update…June 27, 2024

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

TW's Take: this is a very positive update confirming the endpoint's effectiveness and the trial design. We are nearing the end of enrollment, with...

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for...

TW's Take: very positive update as they remain on track and on budget for getting their pivotal trial approved and launched later in 2024. ...

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

TW's Take: enrollment is going much better now as it appears that the safety profile is excellent while there are initial signs of efficacy....

The Roller Coaster Ride Continues Unabated

This week the action in IN8bio (INAB) pretty much sums up the last couple years for growth focused micro-caps. The stock made a nice...

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients...

TW's Take: more outstanding data from INAB. The program is expensive but appears to be successful in keeping patients alive. 100% of treated leukemia...

PERMA-FIX ENVIRONMENTAL SERVICES PROVIDES FURTHER UPDATES ON PATENT-PENDING PROCESS FOR DESTRUCTION OF PFAS COMPOUNDS

TW's Take: this is a great opportunity for PESI and we look forward to seeing what kind of revenues can be generated by this...

Mind the Gap…Micro Performance Continues to Suffer

This week we had a chance to interview Dr. Harlan Weisman, the CEO of TFF Pharma (TFFP). Dr. Weisman related the current travails at...

TFF Pharma…An Interview With The CEO

Despite turning the company around operationally, shares of TFF Pharma (TFFP) have fallen dramatically since Dr. Harlan Weisman took over the reins as CEO...

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American...

TW's Take: good data as INAB continues to show efficacy in a very difficult disease. 92% of evaluable patients treated with INB-200 for glioblastoma...

Cautious on The Market

For pre-revenue companies, times are tough. Funding remains incredibly hard to come by and, for those who display any weakness, the markets are simply...

Aeluma Wins Another Funding Award from the Office of Secretary of Defense

TW's Take: more positive execution on orders that prove the technology while helping keep the burn low while we await the big mobile and...

June Gloom

In San Diego, one might think that June would be one of the best months for weather. You would be partially right. Almost every...

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations...

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program...

TW's Take: while this won't result in revenue any time soon, it's further proof of the technology. As TAC moves into its pivotal trial,...

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.